1

ALX Oncology

Oncology

www.alxoncology.com

HBM contact: Dr Priyanka Belawat

Company status: private

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. The lead candidate, ALX148, a next generation CD47 myeloid checkpoint inhibitor, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to maximize the clinical benefit of anti-cancer therapeutics and is in clinical development for a broad range of tumor types.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171